Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023

• DOI: 10.15585/mmwr.mm7217a3
• Publication Date: 2023-04-27T12:53:24Z
• Authors: Jennifer DeCuir; Diya Surie; Yuwei Zhu; Manjusha Gaglani; Adit A. Ginde; David J. Douin; H. Keipp Talbot; Jonathan D. Casey; Nicholas M. Mohr; Tresa McNeal; Shekhar Ghamande; Kevin W. Gibbs; D. Clark Files; David N. Hager; Minh Phan; Matthew E. Prekker; Michelle N. Gong; Amira Mohamed; Nicholas J. Johnson; Jay S. Steingrub; Ithan D. Peltan; Samuel M. Brown; Emily T. Martin; Arnold S. Monto; Akram Khan; William S. Bender; Abhijit Duggal; Jennifer G. Wilson; Nida Qadir; Steven Y. Chang; Christopher Mallow; Jennie H. Kwon; Matthew C. Exline; Adam S. Lauring; Nathan I. Shapiro; Cristie Columbus; Robert Gottlieb; Ivana A. Vaughn; Mayur Ramesh; Lois E. Lamerato; Basmah Safdar; Natasha Halasa; James D. Chappell; Carlos G. Grijalva; Adrienne Baughman; Kelsey N. Womack; Jillian P. Rhoads; Kimberly W. Hart; Sydney A. Swan; Nathaniel Lewis; Meredith L. McMorrow; Wesley H. Self
• Keywords: Pandemic

As of April 2023, the COVID-19 pandemic has resulted in 1.1 million deaths United States, with approximately 75% occurring among adults aged ≥65 years (1). Data on durability protection provided by monovalent mRNA vaccination against critical outcomes are limited beyond Omicron BA.1 lineage period (December 26, 2021-March 2022). In this case-control analysis, effectiveness 2-4 vaccine doses was evaluated COVID-19-associated invasive mechanical ventilation (IMV) and in-hospital death immunocompetent ≥18 during February 1, 2022-January 31, 2023. Vaccine (VE) IMV 62% 69% those years. When stratified time since last dose, VE 76% at 7-179 days, 54% 180-364 56% ≥365 days. Monovalent substantial, durable variant period. All should remain up to date recommended prevent outcomes.